Streptozotocin therapy in 22 cancer patients
Authors:
Abstract
Twenty-two cancer patients were treated with Streptozotocin (SZN) in six weekly intravenous doses of 1.0–1.5 g/m2. The results of the initial courses of therapy include 3 complete and 2 partial responses, 11 patients with no change, 4 with progression, and 2 deaths due to tumor progression. Three additional deaths also due to tumor progression occurred in previously responding patients. All responses were in patients with pancreatic tumor. Toxicity consisted of transient proteinuria in 11/15 patients, transient azotemia in 11/18 patients, marked reduction of creatinine clearance in 1 patient, burning pain at site of injection, nausea, and vomiting in 20/22 patients, change of FBS from pretherapy to post-therapy of at least 10 mg/100 ml in 11/17 patients, significantly decreased platelet count in 1/22 patients, decreased Hgb in 2/22 patients, and duodenal ulcer in 2/22 patients. A reduced dosage schedule and combination with other drugs known to be effective in pancreatic tumors deserves further investigation.Keywords
This publication has 15 references indexed in Scilit:
- Streptozotocin for Malignant Insulinomas and Carcinoid TumorArchives of internal medicine (1960), 1973
- Islet Cell Tumors: Current Concepts and ManagementAnnals of Internal Medicine, 1973
- Streptozotocin-induced lactic acidosisThe American Journal of the Medical Sciences, 1973
- Streptozotocin Treatment of Metastatic Carcinoid TumorsSouthern Medical Journal, 1972
- Treatment of malignant insulinoma with streptozotocinDiabetologia, 1971
- Streptozotocin and Metastatic InsulinomaAnnals of Internal Medicine, 1971
- Notes on streptozotocin in metastatic insulinomaJournal of Surgical Oncology, 1971
- POTENTIAL CARCINOGENIC EFFECT OF STREPTOZOTOCINThe Lancet, 1969
- TREATMENT OF MULTIPLE-HORMONE-PRODUCING MALIGNANT ISLET-CELL TUMOUR WITH STREPTOZOTOCINThe Lancet, 1968
- Induction of Renal Tumour by Streptozotocin in RatsNature, 1967